Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBT: 2010-2025

Historic EBT for Niagen Bioscience (NAGE) over the last 14 years, with Sep 2025 value amounting to $4.8 million.

  • Niagen Bioscience's EBT rose 155.59% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 1331.11%. This contributed to the annual value of $8.9 million for FY2024, which is 279.32% up from last year.
  • Niagen Bioscience's EBT amounted to $4.8 million in Q3 2025, which was up 28.45% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's EBT registered a high of $7.5 million during Q4 2024, and its lowest value of -$8.9 million during Q3 2021.
  • Over the past 3 years, Niagen Bioscience's median EBT value was $114,000 (recorded in 2023), while the average stood at $1.6 million.
  • In the last 5 years, Niagen Bioscience's EBT crashed by 110.11% in 2021 and then soared by 25,013.33% in 2025.
  • Quarterly analysis of 5 years shows Niagen Bioscience's EBT stood at -$5.3 million in 2021, then skyrocketed by 72.88% to -$1.4 million in 2022, then spiked by 107.89% to $114,000 in 2023, then soared by 6,464.91% to $7.5 million in 2024, then skyrocketed by 155.59% to $4.8 million in 2025.
  • Its EBT was $4.8 million in Q3 2025, compared to $3.7 million in Q2 2025 and $5.2 million in Q1 2025.